| Aug 6 |
Exelixis Announces U.S. Food and Drug Administration (FDA) Accepted the Supplemental New Drug Application for Cabozantinib for Patients with Advanced Neuroendocrine Tumors
|
| Aug 6 |
US Stocks Set To Open Higher After Monday's Crash, VIX Plummets: Analyst Says Would Have Worried If Market Surged Higher Without Correction
|
| Aug 5 |
Exelixis Q2 2024 Earnings Preview
|
| Aug 5 |
What Analyst Projections for Key Metrics Reveal About Exelixis (EXEL) Q2 Earnings
|
| Jul 30 |
Exelixis (EXEL) Reports Next Week: Wall Street Expects Earnings Growth
|
| Jul 23 |
Exelixis to Release Second Quarter 2024 Financial Results on Tuesday, August 6, 2024
|
| Jul 9 |
7 Cheap Biotech Stocks With Major Upside Potential
|
| Jun 27 |
The 23% return delivered to Exelixis' (NASDAQ:EXEL) shareholders actually lagged YoY earnings growth
|
| Jun 7 |
Insider Sale: Director Jack Wyszomierski Sells Shares of Exelixis Inc (EXEL)
|
| May 31 |
Over $8M Bet On This Health Care Stock? Check Out These 4 Stocks Insiders Are Buying
|
